On or around 02/10/2020 (Date of last review)
Filing Date: August 25, 2018
According to the Complaint, Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") is a biopharmaceutical company which focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States.
The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio’s AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampion; (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.
On September 27, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on December 10.
Company & Securities Information
Defendant: Ampio Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: AMPE
Company Market: New York SE
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Jun Shi, et al. v. Ampio Pharmaceuticals, Inc., et al.